BioLargo (BLGO) grants CFO 300,000 stock options at $0.179

Rhea-AI Filing Summary

BioLargo, Inc. reported a new stock option award to its Chief Financial Officer, Charles K. Dargan. On February 1, 2026, he received an option to purchase 300,000 shares of common stock at an exercise price of $0.179 per share. The option becomes exercisable on March 1, 2026 and expires on February 1, 2036. After this grant, he beneficially owned 5,931,668 derivative securities. The filing notes this option was issued as compensation for serving as Chief Financial Officer from February 1, 2026 through January 31, 2027.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DARGAN CHARLES K

(Last) (First) (Middle)

18851 NE 29TH AVENUE

SUITE 700

(Street)

AVENTURA FL 3318

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.179	02/01/2026		A		300,000		03/01/2026	02/01/2036	Common Stock	300,000	(1)	5,931,668	D

Explanation of Responses:

1. This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2026, through January 31, 2027.

	/s/ John R. Browning, attorney-in-fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does BioLargo (BLGO) disclose in this Form 4 filing?

The filing shows BioLargo granted its Chief Financial Officer a stock option for 300,000 shares of common stock at $0.179 per share, with specific vesting and expiration terms defined in the award.

Who is the insider in BioLargo (BLGO)'s latest Form 4 and what is their role?

The reporting person is Charles K. Dargan, who serves as BioLargo’s Chief Financial Officer. The option grant compensates him for serving in this role from February 1, 2026 through January 31, 2027.

What are the key terms of the 300,000 BioLargo (BLGO) stock options?

The Form 4 reports an option to purchase 300,000 shares of BioLargo common stock at an exercise price of $0.179 per share, exercisable starting March 1, 2026 and expiring on February 1, 2036.

When do the new BioLargo (BLGO) CFO stock options vest and expire?

According to the filing, the option becomes exercisable on March 1, 2026 and expires on February 1, 2036. This defines a 10-year term during which the Chief Financial Officer can choose to exercise the award.

How many derivative securities does the BioLargo (BLGO) CFO hold after this transaction?

Following the reported stock option grant, the Chief Financial Officer beneficially owned 5,931,668 derivative securities. This figure includes the new option for 300,000 shares and reflects his total derivative position after the transaction.

Why was the 300,000-share option granted to the BioLargo (BLGO) CFO?

The footnote explains the option was issued as compensation for serving as BioLargo’s Chief Financial Officer from February 1, 2026 through January 31, 2027, aligning the award with his term in that executive role.